share_log

ICU Medical (NASDAQ:ICUI) & Quoin Pharmaceuticals (NASDAQ:QNRX) Head to Head Review

ICU Medical (NASDAQ:ICUI) & Quoin Pharmaceuticals (NASDAQ:QNRX) Head to Head Review

ICU醫療公司(納斯達克代碼:ICUI)和奎因製藥公司(納斯達克代碼:QNRX)正面交鋒
Defense World ·  2022/08/10 02:03

ICU Medical (NASDAQ:ICUI – Get Rating) and Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

ICU Medical(納斯達克:ICUI-GET Rating)和Quoin PharmPharmticals(納斯達克:QNRX-GET Rating)都是醫療公司,但哪隻股票更優越?我們將根據分析師推薦的風險、盈利能力、股息、收益、估值和機構持股情況對這兩家公司進行比較。

Risk & Volatility

風險與波動性

ICU Medical has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.

ICU Medical的貝塔係數為0.55,表明其股價的波動性比標準普爾500指數低45%。相比之下,Quoin PharmPharmticals的貝塔係數為1.63,表明其股價的波動性比標準普爾500指數高出63%。

Get
到達
ICU Medical
ICU醫療
alerts:
警報:

Analyst Ratings

分析師評級

This is a summary of recent ratings and target prices for ICU Medical and Quoin Pharmaceuticals, as provided by MarketBeat.

這是MarketBeat提供的ICU Medical和Quoin PharmPharmticals最近的評級和目標價格摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ICU Medical 0 0 2 0 3.00
Quoin Pharmaceuticals 0 0 3 0 3.00
銷售評級 保持評級 購買評級 強勁的買入評級 評級分數
ICU醫療 0 0 2 0 3.00
Quoin製藥公司 0 0 3 0 3.00
ICU Medical presently has a consensus target price of $207.50, indicating a potential upside of 24.77%. Quoin Pharmaceuticals has a consensus target price of $50.00, indicating a potential upside of 880.39%. Given Quoin Pharmaceuticals' higher possible upside, analysts plainly believe Quoin Pharmaceuticals is more favorable than ICU Medical.
ICU Medical目前的共識目標價為207.50美元,表明潛在漲幅為24.77%。Quoin PharmPharmticals的共識目標價為50美元,表明潛在上漲880.39。考慮到Quoin PharmPharmticals更有可能的上行空間,分析師顯然認為Quoin PharmPharmticals比ICU Medical更有利。

Profitability

盈利能力

This table compares ICU Medical and Quoin Pharmaceuticals' net margins, return on equity and return on assets.

此表比較了ICU醫療公司和Quoin製藥公司的淨利潤率、股本回報率和資產回報率。

Net Margins Return on Equity Return on Assets
ICU Medical 2.68% 7.89% 5.33%
Quoin Pharmaceuticals N/A N/A -355.59%
淨利潤率 股本回報率 資產回報率
ICU醫療 2.68% 7.89% 5.33%
Quoin製藥公司 不適用 不適用 -355.59%

Earnings & Valuation

收益與估值

This table compares ICU Medical and Quoin Pharmaceuticals' top-line revenue, earnings per share and valuation.

此表比較了ICU Medical和Quoin PharmPharmticals的營收、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ICU Medical $1.32 billion 3.02 $103.14 million $2.04 81.52
Quoin Pharmaceuticals N/A N/A -$21.46 million N/A N/A
總收入 價格/銷售額比 淨收入 每股收益 市盈率
ICU醫療 13.2億美元 3.02 1.0314億美元 $2.04 81.52
Quoin製藥公司 不適用 不適用 -2146萬美元 不適用 不適用

ICU Medical has higher revenue and earnings than Quoin Pharmaceuticals.

ICU醫療公司的收入和收益高於Quoin製藥公司。

Institutional & Insider Ownership

機構與內部人持股

94.9% of ICU Medical shares are held by institutional investors. Comparatively, 21.7% of Quoin Pharmaceuticals shares are held by institutional investors. 7.3% of ICU Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ICU醫療94.9%的股份由機構投資者持有。相比之下,Quoin製藥公司21.7%的股份由機構投資者持有。ICU醫療7.3%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一隻股票有望實現長期增長。

Summary

摘要

ICU Medical beats Quoin Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

ICU Medical在兩隻股票比較的10個因素中有7個擊敗了Quoin PharmPharmticals。

About ICU Medical

關於ICU醫療

(Get Rating)

(獲取評級)

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

ICU醫療公司及其子公司在全球範圍內開發、製造和銷售用於輸液治療和危重護理應用的醫療設備。該公司的輸液治療產品包括MicroClave、MicroClave Clear和NanoClave品牌的無針產品;中子導管通暢設備;SwabCap和SwabTip消毒帽;Tego血液透析連接器;ClearGuard HD,血液透析導管的抗菌屏障帽;ChemoClave和ChemoLock封閉式系統傳輸設備,以及用於製備危險藥物的Diana危險藥物複合系統。它還提供靜脈治療和稀釋劑,如氯化鈉、葡萄糖、平衡電解質溶液、乳酸林格氏症、林格氏症、甘露醇、氯化鈉/葡萄糖和無菌水;灌溉包括氯化鈉和無菌水灌溉、生理溶液、林格氏灌溉、醋酸灌溉、甘氨酸灌溉、山梨醇-甘露醇灌溉、彈性容器和灌裝瓶選項。該公司提供Plum 360和LifeCare PCA品牌的輸液泵;IV中介安全軟件,包括ICU Medical MedNet,這是一個企業級藥物管理平臺,將智能泵連接到醫院的電子健康記錄、資產跟蹤系統和警報通知平臺;以及相關專業服務。該公司還提供重症監護產品,如Cogent二合一和心臟Flo血流動力學監測系統;TDQ和OptiQ心輸出量監測導管;TriOx靜脈血氧儀導管;TRANSPAC血壓傳感器;以及SafeSet封閉式血液採樣和保存系統。該公司將其產品銷售給急性護理醫院、批發商、門診診所和備用場所設施,包括門診診所、家庭保健提供者和長期護理設施。ICU醫療, 公司成立於1984年,總部設在加利福尼亞州聖克萊門特。

About Quoin Pharmaceuticals

Quoin製藥公司簡介

(Get Rating)

(獲取評級)

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Quoin PharmPharmticals,Ltd.是一家專業製藥公司,專注於開發治療罕見和孤兒疾病的產品。該公司的主導產品是QRX003,一種治療Netherton綜合徵的外用洗劑。它還開發了用於治療營養不良性大皰性表皮鬆解症的QRX004;以及治療罕見皮膚病的QRX006。該公司總部設在弗吉尼亞州的阿什伯恩。

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受ICU醫學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ICU醫療及相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論